Quick Answer
MBX Biosciences, Inc. reported Net Income of -$86.97 million for fiscal year 2025.
MBX Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$86.97M -40.5% |
-$61.92M -90.2% |
-$32.56M | — |
| Diluted EPS | -$2.38 +59.1% |
-$5.82 +81.8% |
-$31.96 | — |
| Total Assets | $385.14M +43.4% |
$268.54M +219.0% |
$84.18M | — |
| Cash and Equivalents | $75.29M +52.6% |
$49.35M +61.7% |
$30.52M | — |
| Stockholders Equity | $369.22M +43.4% |
$257.44M +455.2% |
-$72.47M -70.1% |
-$42.60M |
| R&D Expense | $79.16M +37.9% |
$57.41M +101.2% |
$28.53M | — |
| Operating Income | -$98.06M -43.8% |
-$68.19M -93.1% |
-$35.31M | — |
| Shares Outstanding | 44.93M +34.4% |
33.42M +2558.7% |
1.26M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$21.62M | -19.2% | -11.4% |
| Diluted EPS | September 30, 2025 | -$0.63 | +77.3% | -8.6% |
| Total Assets | September 30, 2025 | $400.08M | +41.7% | +72.8% |
| Cash and Equivalents | September 30, 2025 | $223.12M | +67.9% | +460.9% |
| Stockholders Equity | September 30, 2025 | $387.54M | +42.8% | +76.8% |
| R&D Expense | September 30, 2025 | $19.27M | +15.1% | +8.7% |
| Operating Income | September 30, 2025 | -$23.93M | -22.0% | -9.7% |
| Shares Outstanding | September 30, 2025 | 44.72M | +34.0% | +33.1% |
- MBX Biosciences, Inc. reported Net Income of -$86.97 million for fiscal year 2025.
- MBX Biosciences, Inc. showed a decrease of -40.5% in Net Income compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Diluted EPS of $2.38 per share (loss) for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +59.1% in Diluted EPS compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Total Assets of $385.14 million for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +43.4% in Total Assets compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Cash and Equivalents of $75.29 million for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +52.6% in Cash and Equivalents compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Stockholders Equity of $369.22 million for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +43.4% in Stockholders Equity compared to the prior fiscal year.
- MBX Biosciences, Inc. reported R&D Expense of $79.16 million for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +37.9% in R&D Expense compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Operating Income of -$98.06 million for fiscal year 2025.
- MBX Biosciences, Inc. showed a decrease of -43.8% in Operating Income compared to the prior fiscal year.
- MBX Biosciences, Inc. reported Shares Outstanding of 44.93 million shares for fiscal year 2025.
- MBX Biosciences, Inc. showed an increase of +34.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: